Synovial-Targeted Biomimetic Nanoparticle: Dual Cytokine Blockade (TNF- α and IL-6) Through Intra-Articular Delivery in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovitis, marked by massive immune-cell infiltration and hyperplasia of the synovial membrane. This leads to irreversible joint destruction, cartilage degradation, bone erosion, severe disability, reduced quality of life, and a substantial socioeconomic burden. The core of this pathology is the overproduction of proinflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), by activated macrophages and fibroblast-like synoviocytes in the inflamed synovium. Biomimetic membrane-coated nanoparticles have emerged as highly promising platforms for the precise targeting of TNF-α and IL-6. By coating synthetic cores with natural cell membranes such as those derived from macrophages, neutrophils, or synovial fibroblasts, these systems enable immune evasion, site-specific inflammatory homing, and dual functionality as cytokine decoys while facilitating controlled intracellular delivery of therapeutics. Compared with conventional therapies, intra-articular administration further enhances their potential by providing direct access to the synovial membrane, prolonging local retention, and minimizing systemic exposure. The preclinical evidence base remains limited — largely single-group, non-replicated studies using CIA models of uncertain human predictive value — and clinical translation faces several major hurdles. Lay Summary Rheumatoid arthritis is a long-term disease causing painful joint inflammation, driven mainly by proteins TNF-α and IL-6. Current drugs target these proteins, but systemic treatments often cause side effects or fail to work for everyone. This review explores a novel approach using biomimetic nanoparticles coated with natural cell membranes to deliver drugs directly into the joint. These cell coatings help nanoparticles target inflamed tissue, avoid immune detection, and neutralize inflammatory proteins locally. While early animal studies are promising, clinical trials in humans are still needed. This localized delivery method could lead to safer, more effective treatments for rheumatoid arthritis. Future Works Description Future research will focus on scaling up standardized, cost-effective manufacturing of membrane-coated nanoparticles while ensuring batch-to-batch consistency. Comprehensive long-term safety, biocompatibility, and pharmacokinetic evaluations in relevant models are required, alongside establishing standardized regulatory frameworks to enable successful translation from preclinical studies to human clinical trials for rheumatoid arthritis. Graphical Abstract

Authors

Institutions

Publication Details

Journal
Regenerative Engineering and Translational Medicine
Published
2026-11-12
DOI
https://doi.org/10.1007/s40883-026-00643-w
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Synovial-Targeted Biomimetic Nanoparticle: Dual Cytokine Blockade (TNF- α and IL-6) Through Intra-Articular Delivery in Rheumatoid Arthritis

Dakshinesh Parameswaran, Damodharan Narayanasamy, Praveen Kumar Pridvi Venkatesan
Regenerative Engineering and Translational Medicine
Rheumatoid Arthritis Research and Therapies
article

Synovial-Targeted Biomimetic Nanoparticle: Dual Cytokine Blockade (TNF- α and IL-6) Through Intra-Articular Delivery in Rheumatoid Arthritis

Dakshinesh Parameswaran, Damodharan Narayanasamy, Praveen Kumar Pridvi Venkatesan
article en

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovitis, marked by massive immune-cell infiltration and hyperplasia of the synovial membrane. This leads to irreversible joint destruction, cartilage degradation, bone erosion, severe disability, reduced quality of life, and a substantial socioeconomic burden. The core of this pathology is the overproduction of proinflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), by activated macrophages and fibroblast-like synoviocytes in the inflamed synovium. Biomimetic membrane-coated nanoparticles have emerged as highly promising platforms for the precise targeting of TNF-α and IL-6. By coating synthetic cores with natural cell membranes such as those derived from macrophages, neutrophils, or synovial fibroblasts, these systems enable immune evasion, site-specific inflammatory homing, and dual functionality as cytokine decoys while facilitating controlled intracellular delivery of therapeutics. Compared with conventional therapies, intra-articular administration further enhances their potential by providing direct access to the synovial membrane, prolonging local retention, and minimizing systemic exposure. The preclinical evidence base remains limited — largely single-group, non-replicated studies using CIA models of uncertain human predictive value — and clinical translation faces several major hurdles. Lay Summary Rheumatoid arthritis is a long-term disease causing painful joint inflammation, driven mainly by proteins TNF-α and IL-6. Current drugs target these proteins, but systemic treatments often cause side effects or fail to work for everyone. This review explores a novel approach using biomimetic nanoparticles coated with natural cell membranes to deliver drugs directly into the joint. These cell coatings help nanoparticles target inflamed tissue, avoid immune detection, and neutralize inflammatory proteins locally. While early animal studies are promising, clinical trials in humans are still needed. This localized delivery method could lead to safer, more effective treatments for rheumatoid arthritis. Future Works Description Future research will focus on scaling up standardized, cost-effective manufacturing of membrane-coated nanoparticles while ensuring batch-to-batch consistency. Comprehensive long-term safety, biocompatibility, and pharmacokinetic evaluations in relevant models are required, alongside establishing standardized regulatory frameworks to enable successful translation from preclinical studies to human clinical trials for rheumatoid arthritis. Graphical Abstract

Regenerative Engineering and Translational Medicine
SRM Institute of Science and Technology (IN)
Good health and well-being
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon